Aclarion (NASDAQ:ACON), a commercial-stage healthcare technology company, has closed a $10.4 million common-stock-only financing, significantly bolstering its balance sheet as it seeks to transform the diagnosis of chronic low back pain.
The capital raise, priced at $5.18 per share, was executed under a "clean" structure designed to preserve the integrity of the company’s capital table.
The funding provides Aclarion with a substantial financial cushion during a critical phase of commercial scaling.
As of Jan. 12, 2026, the company reported a cash balance of $21.6 million and maintains a debt-free status.
Management indicates that this strengthened position extends the company’s operating runway into 2028, covering several key clinical and commercial catalysts.
The primary driver for Aclarion is its Nociscan platform, the first SaaS tool to use MR Spectroscopy and proprietary augmented intelligence (AI) to non-invasively identify the chemical biomarkers of discogenic pain.
By helping physicians distinguish between painful and non-painful discs, the technology aims to improve surgical success rates, which currently hover around 54% for chronic low back pain.
Proceeds from the financing are earmarked for the continued expansion of Nociscan’s commercial footprint and the advancement of the pivotal CLARITY trial.
Aclarion is currently targeting approximately 25% patient enrollment in the trial by the end of the second quarter of 2026, with interim data readouts expected to follow shortly thereafter.
This evidence generation is viewed as a vital step toward securing broader payer coverage and establishing Nociscan as a standard of care in spinal diagnostics.